Etodolac-d4

Etodolac-d4 (AY-24236-d4) is deuterium labeled Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)

Product Specifications

Product Name Alternative

AY-24236-d4

UNSPSC

12352005

Target

COX; Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C(CC1(CC)OC([2H])([2H])C([2H])([2H])C2=C1NC3=C2C=CC=C3CC)O

Molecular Formula

C17H17D4NO3

Molecular Weight

291.38

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121 (1) :105-17.|[3]Ito S, Tajima K, Nogawa M et al. Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. J Pharmacol Exp Ther. 2012 Jul;342 (1) :53-60.|[4]Yanaoka K, Oka M, Yoshimura N et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer. 2010 Mar 15;126 (6) :1467-73.|[5]Matsuyama M, Yoshimura R, Hase T et al. Administration of the selective cyclooxygenase (COX) -2 inhibitor etodolac prolongs cardiac allograft survival in a mouse model. Mol Med Report. 2010 Sep-Oct;3 (5) :771-4.